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ABSTRACT
ObjeCtives
To examine the association between dipeptidyl 
peptidase-4 (DPP-4) inhibitors and the risk of heart 
failure or hospital admission for heart failure in 
patients with type 2 diabetes.
Design
Systematic review and meta-analysis of randomised 
and observational studies.
Data sOurCes
Medline, Embase, Cochrane Central Register of 
Controlled Trials, and ClinicalTrials.gov searched up to 
25 June 2015, and communication with experts.
eligibility Criteria
Randomised controlled trials, non-randomised 
controlled trials, cohort studies, and case-control 
studies that compared DPP-4 inhibitors against 
placebo, lifestyle modification, or active antidiabetic 
drugs in adults with type 2 diabetes, and explicitly 
reported the outcome of heart failure or hospital 
admission for heart failure.
Data COlleCtiOn anD analysis
Teams of paired reviewers independently screened for 
eligible studies, assessed risk of bias, and extracted 
data using standardised, pilot tested forms. Data from 
trials and observational studies were pooled 
separately; quality of evidence was assessed by the 
GRADE approach.
results
Eligible studies included 43 trials (n=68 775) and 12 
observational studies (nine cohort studies, three 
nested case-control studies; n=1 777 358). Pooling of 
38 trials reporting heart failure provided low quality 
evidence for a possible similar risk of heart failure 
between DPP-4 inhibitor use versus control (42/15 701 v 
33/12 591; odds ratio 0.97 (95% confidence interval 
0.61 to 1.56); risk difference 2 fewer (19 fewer to 28 
more) events per 1000 patients with type 2 diabetes 
over five years). The observational studies provided 
effect estimates generally consistent with trial 
findings, but with very low quality evidence. Pooling of 
the five trials reporting admission for heart failure 
provided moderate quality evidence for an increased 
risk in patients treated with DPP-4 inhibitors versus 
control (622/18 554 v 552/18 474; 1.13 (1.00 to 1.26); 8 
more (0 more to 16 more)). The pooling of adjusted 
estimates from observational studies similarly 
suggested (with very low quality evidence) a possible 
increased risk of admission for heart failure (adjusted 
odds ratio 1.41, 95% confidence interval 0.95 to 2.09) 
in patients treated with DPP-4 inhibitors (exclusively 
sitagliptin) versus no use.
COnClusiOns
The relative effect of DPP-4 inhibitors on the risk of 
heart failure in patients with type 2 diabetes is 
uncertain, given the relatively short follow-up and low 
quality of evidence. Both randomised controlled trials 
and observational studies, however, suggest that 
these drugs may increase the risk of hospital 
admission for heart failure in those patients with 
existing cardiovascular diseases or multiple risk 
factors for vascular diseases, compared with no use.
Introduction
Of over 380 million people with diabetes worldwide, 
most (85-95%) have type 2 diabetes.1  Dipeptidyl pepti-
dase-4 (DPP-4) inhibitors are a relatively new class of 
incretin based agents for treating type 2 diabetes. Evi-
dence from randomised controlled trials has estab-
lished that DPP-4 inhibitors reduce levels of glycated 
haemoglobin (HbA1c),2 3 do not affect body weight,2 
pose a low risk of hypoglycaemia,4  and do not increase 
the risk of cardiovascular events.5-7 The American Dia-
betes Association and European Association for the 
Study of Diabetes have recommended this drug class as 
second line agents for type 2 diabetes management.8
A recent major trial9 (SAVOR-TIMI 53) reported an 
increased risk of admission to hospital for heart failure 
(hazard ratio 1.27, 95% confidence interval 1.07 to 1.51) 
with the DPP-4 inhibitor saxagliptin. Although unex-
pected, the finding raised concern among professionals 
and health authorities. In 2014, the US Food and Drug 
WhAT IS AlReAdy knoWn on ThIS TopIC
Several occurrences of heart failure or hospital admission for heart failure have 
been reported in patients with type 2 diabetes taking DPP-4 inhibitors
Systematic reviews of randomised controlled trials and observational studies have 
suggested an increased risk of heart failure or admission for heart failure 
associated with the agents
WhAT ThIS STudy AddS
The relative effect of DPP-4 inhibitors on the risk of heart failure is uncertain
Current evidence from trials and observational studies suggests a small increase in 
risk of admission for heart failure in patients with type 2 diabetes who have existing 
cardiovascular diseases or multiple risk factors for vascular diseases, relative to 
no use
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Administration (FDA) requested the clinical trial data 
from the manufacturer to investigate the potential asso-
ciation between use of saxagliptin and heart failure. 
The FDA then recommended that “Patients should not 
stop taking saxagliptin and should speak with their 
health care professionals about any questions or con-
cerns. Health care professionals should continue to fol-
low the prescribing recommendations in the drug 
labels.”10
Subsequently, the EXAMINE trial11  testing alogliptin, 
and the TECOS trial12  testing sitagliptin, reported no 
significant effect on hospital admission for heart fail-
ure. Evidence from observational studies has been 
inconsistent,13-17 and the effect of DPP-4 inhibitors on 
heart failure remains controversial.
A systematic review of trials and observational stud-
ies offers an opportunity to consider the total body of 
evidence and potentially resolve the concern. We there-
fore undertook a systematic review to assess the extent 
to which DPP-4 inhibitors affect the risk of heart failure 
or hospital admission for heart failure in patients with 
type 2 diabetes.
Methods
We followed the standards set by the meta-analysis of 
observational studies in epidemiology (MOOSE)18  and 
preferred reporting items for systematic reviews and 
meta-analyses (PRISMA)19 for the reporting of our study.
eligibility criteria
We included randomised controlled trials, non-ran-
domised controlled trials, cohort studies, and case-con-
trol studies that compared DPP-4 inhibitors against 
placebo, lifestyle modification, or active antidiabetic 
drugs in adults with type 2 diabetes. We required fol-
low-up for at least 12 weeks (not applicable to case- 
control studies), and explicit reporting of the outcome 
of heart failure or hospital admission for heart failure 
(either as raw data or adjusted effect estimates with 
95% confidence intervals). We classified study designs 
according to recommendations by the Cochrane 
Non-Randomised Studies Methods Group. Trials, par-
ticularly phase III studies, reported heart failure either 
as a normal adverse event or a serious adverse event. 
For serious adverse events, admission for heart failure 
may have been included. We defined heart failure 
reported in such trials as an unspecified outcome.
literature search
We searched Medline, Embase, and the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) from incep-
tion to 25 June 2015. We combined both MeSH and free 
text terms for identifying relevant articles. An informa-
tion expert (DP) developed our search strategies (web 
appendix 1).
We also searched ClinicalTrials.gov to identify addi-
tional eligible studies. Section 801 of the US Food and 
Drug Administration Amendments Act (FDAAA 801) 
requires responsible parties to submit summary results 
of clinical trials, including serious adverse events and 
adverse events with frequency over 5%, to this trial 
 registry.20 21 In doing so, important information regard-
ing heart failure can be collected. We used generic 
names of each drug to identify relevant studies, and 
limited our search to studies labelled as “completed” or 
“terminated,” in which summary results were available.
We also contacted content experts and industry repre-
sentatives, and searched for conference abstracts on the 
American Diabetes Association and European Associa-
tion for the Study of Diabetes, for additional information.
study process
Teams of two paired reviewers, trained in health research 
methods, independently screened titles, abstracts, and 
full texts for eligibility; assessed risk of bias; and col-
lected data from each eligible study, using standardised, 
pilot tested forms, together with detailed instructions. 
Reviewers resolved disagreement through discussion or, 
if required, by adjudication by a third reviewer (XS).
risk of bias assessment
We used the Cochrane Collaboration’s tool22  to assess 
the risk of bias of randomised controlled trials. The 
items included random sequence generation, alloca-
tion concealment, blinding of participants, caregivers, 
and assessors of outcomes (that is, heart failure or hos-
pital admission for heart failure), and adjudication of 
the outcomes. By assessing the risk of bias associated 
with blinding of patients, caregivers, and outcome 
assessors, we modified the instrument by removing the 
“unclear” option, an approach that we have previously 
shown to be reliable and valid.23
We used the Newcastle-Ottawa quality assessment 
scale24 to assess the risk of bias of cohort studies and 
case-control studies. We removed the items “representa-
tiveness of the exposed cohort” and “was follow-up long 
enough for outcomes to occur” for cohort studies and the 
item “representativeness of the cases” for case-control 
studies because these items relate to applicability of 
results. We, however, added two items: the ascertainment 
of type 2 diabetes and the ascertainment of potential con-
founding factors for these both types of studies, because 
misclassification could result from suboptimal approaches 
to these issues. We planned to assess publication bias but 
were unable to do so owing to very low event rates.
Data collection
We collected the following information from each eligi-
ble randomised controlled trial:
•	 General study characteristics: author name, year of 
publication, total number of patients randomised, 
number of treatment groups, length of follow-up, 
study phase, funding source, trial registry number, 
countries involved, and number of study sites
•	 Patient characteristics: sex, age, diabetes duration, 
body mass index, baseline HbA1c level, and fasting 
plasma glucose values
•	 Interventions: medications common to all groups 
(baseline treatment), details of DPP-4 inhibitors 
treatment and control group (eg, drug generic name, 
and duration of treatment)
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•	 Outcomes: the definition of heart failure, number of 
events, and patients included for analyses in each 
group, as well as adjusted data if available.
For each trial, if the initial treatment assignment was 
switched (eg, patients in placebo group started receiv-
ing DPP-4 inhibitors after 24 weeks), we collected the 
outcome data before that point. If a trial had multiple 
reports, we collated all data into one study.25 If a trial 
had both reports from ClinicalTrials.gov and journal 
publications, we carefully checked data from these two 
sources for  consistency. If outcome data were reported 
at multiple follow-up points, we used data from the lon-
gest follow-up.
For observational studies, we collected data similar to 
randomised controlled trials (eg, total number of patients, 
sex, age, diabetes duration, body mass index, baseline 
HbA1c). We documented, for each observational study, 
the definition of outcomes and sources of data for the out-
comes. In addition, we documented information on:
•	 Study design (eg, retrospective or prospective cohort 
study)
•	 Data source (eg, claims data, electronic medical 
records)
•	 Methods used to ascertain type 2 diabetes status (eg, 
International Classification of Diseases (ICD) code)
•	 Exposures (eg, DPP-4 inhibitors, and other exposure 
variables)
•	 Methods used to control confounding (eg, logistic or 
cox regression, and control variables).
We collected adjusted estimates and their associated 
95% confidence intervals, as well as adjustment factors, 
in addition to raw event data and exposure time.
Data analysis
We conducted separate analyses for randomised con-
trolled trials and observational studies. We also sepa-
rately analysed the data on heart failure and hospital 
admission for heart failure, because those two out-
comes, although sharing the same clinical and patho-
physiological features, represent differential seriousness 
of the effect of DPP-4 inhibitors treatment on patients 
and society. Heart failure could be subclinical and might 
not be diagnosed; admission for heart failure is, how-
ever, always a clinical event and a condition important 
to patients and clinicians. We considered admission for 
heart failure as the more important outcome for patients.
For the analysis of trials, we pooled outcome data 
using Peto’s methods because of very low event 
rates,26 27 and reported pooled Peto odds ratios and 
associated 95% confidence intervals. We examined het-
erogeneity among studies with the Cochrane χ2 test and 
the I2 statistic. We explored sources of heterogeneity 
with four prespecified subgroup hypotheses:
•	 Type of control (placebo v active treatment; larger 
effect in trials with placebo control)
•	 Length of follow-up (≤52 v >52 weeks; larger effect in 
those with longer follow-up)
•	 Mode of treatment (monotherapy v add-on or combi-
nation therapy; larger effect in those with add on or 
combination therapy)
•	 Individual DPP-4 inhibitors (different DPP-4 inhibitors 
v control).
We carried out sensitivity analyses by using alternative 
effect measures (odds ratios v risk ratios), pooling meth-
ods (Peto v Mantel-Hanszel method), and statistical 
models regarding heterogeneity (random v fixed effects).
In the analysis of observational studies, we qualita-
tively summarised the data for heart failure, because of 
the substantial variations in the comparison (that is, type 
of control) and patient populations in those studies. We 
pooled adjusted estimates of hospital admission for 
heart failure from cohort and nested case-control studies 
using a random effects model. Although the effect mea-
sures differ for those two designs (hazard ratios for 
cohort studies and odds ratios for nested case-control 
studies), they are relative measures and the effect esti-
mates are close when the event rate is low (<5%).
Quality of evidence
We used the grading of recommendations assessment, 
development, and evaluation (GRADE) methodology to 
rate quality of the evidence for heart failure and hospi-
tal admission for heart failure as high, moderate, low, 
or very low.28  Randomised controlled trials begin as 
high quality evidence, but can be rated down because 
of risk of bias,29  imprecision,30  inconsistency,31  indi-
rectness,32  and publication bias.33  Observational stud-
ies begin as low quality evidence, but can be rated up 
for a large magnitude of effect, a dose-response gradi-
ent, or presence of plausible confounders or other 
biases that increase confidence in the estimated effect.34
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community.
Results
Of 11 440 potentially relevant reports identified, after 
title and abstract screening, 820 reports proved poten-
tially eligible. On full text screening, 55 studies proved 
eligible, including 43 randomised controlled trials, rep-
resenting 68 775 patients, reported in 77 reports9 11 12 35-108 
(45 from journal reports, 31 from the ClinicalTrials.gov 
website, and one conference abstract) and 12 observa-
tional studies,13-17 109 110 111-115  involving 1 777 358 patients, 
reported in nine cohort studies and three nested 
case-control studies (nine from journal reports, one 
from a trial registry, and two conference abstracts; 
fig  1 ). Two cohort studies15 116 analysed patient data 
from the same claims database, one presenting a sub-
population of the other; we included only the larger 
cohort study.15
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evidence from randomised controlled trials
Trials reporting heart failure
Of the 43 randomised controlled trials, 38 reported 
heart failure, of which 33 (87%) were international stud-
ies, and 35 (92%) were clearly labelled as phase III tri-
als. These 38 trials enrolled 109-2789 patients (total 
n=31 680; mean age range 49.7-72.6 years, mean body 
mass index 24.0-32.8, mean baseline HbA1c 7.1-9.9%, 
mean fasting plasma glucose 7.7-11.1 mmol/L, and mean 
duration of diabetes 1.7-17.5 years; table 1 ). Nine trials 
used DPP-4 inhibitors as monotherapy, 27 as add-on or 
combination therapy, and two as both monotherapy 
and combination therapy. Length of follow-up ranged 
from 12 to 206 weeks (median 52; table 2).
All 38 trials were industry funded. Most (n=24) were 
identified from ClinicalTrials.gov, of which four91-93 96 
have not been published in a peer reviewed journal. 
Because of the limited information in the trial registry, 
we were unable to adequately assess the risk of bias for 
these four trials. On the basis of the information we col-
lected, 16 (42%) trials adequately generated their rando-
misation sequence; 11 (29%) adequately concealed 
allocation; all trials blinded patients, caregivers, and 
outcome assessors; eight (21%) adjudicated heart failure 
events; and four (11%) used blinded assessors to adjudi-
cate heart failure (web appendix 2). The treatment groups 
of each included trial were generally balanced with 
respect to demographic and clinical characteristics.
Effects on heart failure
The 38 trials reported 75 heart failure events occurring in 
28 292 patients who were treated with at least one drug 
(raw event rate 0.27%). The definition of heart failure 
was available in only one trial;37 33 (87%) trials reported 
heart failure as serious adverse events. The pooling of 
data from these trials showed no significant difference 
in the risk of heart failure between DPP-4 inhibitors 
treatment and control. Event rates were 0.27% for DPP-4 
inhibitors versus 0.26% for controls (odds ratio 0.97 
(95% confidence interval 0.61 to 1.56), I2=0%; risk differ-
ence 2 fewer (19 fewer to 28 more) events per 1000 
patients with type 2 diabetes over five years; fig 2  and 
table 3 ). We rated the quality of evidence as low because 
of risk of bias and imprecision (table 3).
The subgroup analysis by type of control (placebo v 
active drugs) showed no difference in treatment effects 
(interaction P=0.57; comparison with placebo, odds 
ratio 1.17 (95% confidence interval 0.58 to 2.33); compar-
ison with active drugs, 0.89 (0.47 to 1.66); fig A in web 
appendix 3). The subgroup analyses of the other three 
prespecified hypotheses showed no difference in treat-
ment effects (figs B-D in appendix 3). Sensitivity analy-
sis using alternative effect measures, statistical 
methods, and analysis models did not show important 
changes in pooled effects (figs E-G in web appendix 3).
Trials reporting hospital admission for heart failure
We included three large trials9 11 12  (SAVOR-TIMI 53, 
EXAMINE, and TECOS) and two small trials104 105  report-
ing hospital admission for heart failure; all were 
designed to assess the cardiovascular safety of DPP-4 
inhibitors compared with placebo (table 1 ). The SAVOR-
TIMI 53 trial investigated saxagliptin in patients with dia-
betes who had a renal impairment and cardiovascular 
disease or multiple risk factors for vascular disease. The 
EXAMINE trial recruited patients receiving alogliptin 
with type 2 diabetes and a recent acute coronary syn-
drome. The TECOS trial examined sitagliptin in patients 
with type 2 diabetes and cardiovascular disease. In addi-
tion, one small trial104  assessed vildagliptin in patients 
with type 2 diabetes as well as heart failure and a left ven-
tricular ejection fraction less than 40%; the other small 
trial105 assessed linagliptin in patients with type 2 diabe-
tes with moderate to severe renal impairment.
All three large trials were international studies. The 
median length of follow-up ranged from 76 to 156 weeks 
(table 1). Those trials enrolled 5380-16 492 patients 
(total n=36 607; mean age range 60.9-65.5 years, mean 
body mass index 29.5-31.1, and duration of diabetes 9.2-
11.6 years). The two small trials followed up patients for 
52 weeks; mean age ranged from 63 to 66.6 years and 
mean HbA1c levels ranged from 7.8% to 8.1%.
All trials, but one104 (which had unclear details 
because it was presented as an abstract), adequately 
generated their randomisation sequence and ade-
quately concealed allocation; all trials blinded patients, 
caregivers, outcome assessors, and centrally adjudi-
cated hospital admission for heart failure outcome 
through a clinical events classification committee who 
were blinded to treatment allocation. All trials were 
funded by industry (web appendix 2).
Effects on hospital admission for heart failure
All five trials9 11 12 104 105 reported unadjusted rates of hos-
pital admission for heart failure. Overall, 1174 events of 
admission for heart failure occurred in 37 028 patients 
Additional records identied (n=334):
  ClinicalTrials.gov (n=329)
  Conference websites (n=5)
Records identied through
database searches (n=11 106)
Records screened (n=8691)
Potentially eligible reports accessed for full text screening (n=820)
Studies included in review (n=55; 89 reports):
  Randomised controlled trials reported in 77 reports (n=43):
    Journal reports (n=45), trial registry reports (n=31), conference abstract (n=1)
  Observational studies (n=12; cohort studies (n=9), nested case-control studies (n=3)):
    Journal reports (n=9), trial registry report (n=1), conference abstracts (n=2)
Records excluded aer title and
abstract screening (n=7871)
Duplicates (n=2749)
Excluded reports (n=731): 
  Improper study design (n=50)
  Inappropriate comparisons (n=77)
  Follow-up less than 12 weeks (n=11)
  Not patients with type 2 diabetes mellitus
    (n=7)
  No heart failure outcome clearly and
    explicitly reported (n=585)
  Data from same claims database (n=1)
Fig 1 | Flowchart of article selection
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(raw event rate 3.4% for DPP-4 inhibitors v 3.0% for 
controls; table 3). Pooling across trials showed a bor-
derline increase in the risk of hospital admission for 
heart failure in patients with type 2 diabetes using 
DPP-4 inhibitors versus control (odds ratio 1.13 (95% 
confidence interval 1.00 to 1.26), I2=0%; risk difference 
8 more (0 more to 16 more) per 1000 patients with type 
2 diabetes over five years; fig 3  and table 3 ). We rated 
the quality of evidence as moderate due to imprecision 
(table 3). Sensitivity analysis by use of alternative effect 
measures, statistical methods, and analysis models did 
not show important changes in the pooled effects (figs 
H-J in web appendix 3).
evidence from observational studies
Of 12 observational studies, four109-112 reported heart 
failure, and eight13-17 113-115 reported hospital admission 
for heart failure; nine13-15 109-111 113-115 were cohort studies 
and the other three16 17 112  were nested case-control  studies 
(fig 1).
table 1 | Characteristics of included randomised controlled trials
author (year)
inter­
national 
study
no of 
countries 
involved
no of 
study 
sites
study 
phase
total no of 
patients 
randomised
length of 
follow­up 
(weeks)
Male 
patients 
(no, %)
Mean 
age 
(years)
Mean 
body mass 
index
Mean 
Hba1c 
(%)
Mean FPg 
(mmol/l)
Mean diabetes 
duration 
(years)
trials reporting heart failure
Arjona Ferreira (2013)a35, 36 Yes NR NR III 426 54 158 (57) 64.5 26.8 7.8 8.1 10.4
Arjona Ferreira (2013)b37, 38 Yes 12 31 III 129 54 77 (59.7) 59.5 26.8 7.8 9.0 17.5*
Bosi (2011)39 Yes NR NR III 803 52 414 (51.6) 55.1 31.5 8.2 9.0 7.2
Ferrannini (2009)40 Yes 24 402 III 2789 52 1490 (53.4) 57.5 31.8 7.3 9.2 5.7
Fonseca (2013)41 Yes 12 58 III 313 26 195 (62.3) 56.0 29.9 9.8 9.8 NR
Garber (2007)42 Yes 2 123 III 463 24 199 (50) 54.0 32.4 8.7 10.1 4.7
Henry (2014)43, 44 NR NR NR III 1615 54 912 (56.5) NR 30.9 8.8 10.0 7.9
Iwamoto (2010)45, 46 Yes 1 97 II 363 12 224 (61.7) 59.8 24.5 7.6 8.2 5.4
NCT00094770 (2009)47, 48, 49 Yes NR 173 III 1172 104 694 (59.2) 56.7 31.2 7.7 9.2 6.4
NCT00103857 (2009)50, 51 Yes NR 140 III 1091 104 539 (49.4) 53.5 NR 8.8 11.1 NR
NCT00121641 (2011)52, 53 NR 6 135 III 403 206 204 (50.9) 53.5 31.7 7.9 9.7 2.6
NCT00121667 (2011)54, 55 Yes 9 154 III 745 206 377 (50.7) 54.6 31.4 NR NR NR
NCT00286442 (2011)56, 57 Yes 15 115 III 527 26 265 (50.3) 54.8 32.0 7.9 9.5 6.0
NCT00286468 (2011)58, 59 Yes 15 125 III 585 26 261 (52.2) 56.6 30.1 NR NR 7.7
NCT00295633 (2009)60, 61, 62 Yes 8 133 III 565 76 643 (49.2) 52.0 30.2 9.5 11.1 1.7
NCT00327015 (2009)63, 64, 65 Yes 13 211 III 1309 24 643 (49.2) 52.0 30.2 9.5 11.1 1.7
NCT00395343 (2009)66, 67 Yes 24 100 III 641 24 326 (50.9) 57.8 31.0 8.7 9.8 12.5
NCT00482729 (2009)68, 69, 70 Yes 2 229 III 1250 44 708 (56.8) 49.7 NR 9.9 NR NR
NCT00575588 (2010)71, 72, 73 Yes 11 130 III 858 104 444 (51.7) 57.5 31.4 7.7 9.0 5.4
NCT00614939 (2010)74, 75, 76 Yes 13 75 III 170 52 73 (42.9) 66.5 30.7 8.3 9.9 16.7
NCT00622284 (2011)77, 78 Yes 16 209 III 1560 104 933 (60.2) 56.6 30.2 7.7 9.1 715 (47.1)†
NCT00642278 (2013)79, 80 Yes 13 85 II 451 12 236 (52.3) 52.9 31.5 7.8 9.0 NR
NCT00707993 (2013)81, 82 Yes 15 110 III 441 54 198 (44.9) 69.9 29.8 7.5 8.1 6.1
NCT00757588 (2011)83, 84 Yes 10 72 III 457 24 188 (41.3) 57.2 32.3 8.7 9.6 11.9
NCT00798161 (2011)85, 86 Yes 14 133 III 791 24 426 (53.9) 55.3 29.1 8.7 10.9 562 (74.3)†
NCT00838903 (2014)87, 88 Yes 10 289 III 1049 164 482 (47.6) 54.5 32.6 8.1 9.2 6.0
NCT00856284 (2013)89, 90 Yes 32 310 III 2639 104 1312 (49.7) 55.4 31.2 7.6 NR 5.5
NCT00954447 (2012)91 Yes 19 167 III 1263 52 658 (52.2) 60.0 31.0 8.3 8.3 NR
NCT01006603 (2013)92 Yes 13 152 IV 720 52 445 (61.8) 72.6 NR NR NR NR
NCT01189890 (2013)93 Yes NR NR III 480 30 202 (42.1) 70.7 NR 7.8 9.4 NR
NCT01263483 (2011)94, 95 No 1 31 II and III 230 12 142 (61.7) 62.1 24.0 8.0 NR 7.8
NCT01289990 (2014)96 Yes 19 243 III 2700 76 1492 (55.3) 55.6 NR NR NR NR
Pratley (2009)97, 98 Yes 14 125 III 493 26 287 (58.2) 55.4 32.8 8.0 NR 7.6
Pratley (2014)99 Yes 13 198 III 784 26 374 (47.7) 53.5 30.7 NR NR 4.0
Rosenstock (2006)100 Yes 17 NR III 353 24 196 (55.5) 56.3 31.5 8.0 9.2 NR
Rosenstock (2010)101 Yes 23 268 III 655 26 320 (48.9) 52.6 31.1 8.8 10.6 3.2
Seino (2012)102 No 1 30 III 288 12 198 (68.8) 52.6 25.9 8.0 NR 6.3
Yang (2015)103 No 1 25 III 109 24 57 (54.3) 56.2 25.0 7.1 7.7 3.6
trials reporting hospital admission for heart failure
Green (2015) (TECOS)12 Yes 38 673 III 14  735 156‡ 10 374 (70.7) 65.5 30.2 7.2 NR 11.6
Krum (2014) (VIVIDD)104 NR NR NR NR 253 52 NR 63 NR 7.8 NR NR
Laakso (2015)105 Yes 9 52 III 235 52 149 (63.4) 66.6 NR 8.1 NR NR
Scirica (2013)  
(SAVOR-TIMI 53)9, 106
Yes 26 788 IV 16  492 109‡ 11 037 (66.9) 65.0 31.1 NR 8.7 10.3*
Zannad (2015) 
(EXAMINE)11, 107, 108
Yes 49 898 III 5380 76‡ 3651 (67.9) 60.9 29.5 NR NR 9.2
FPG=fasting plasma glucose; NR=not reported.
*Median diabetes duration (years).
†No (%) of patients with no more than five years’ duration.
‡Median follow-up time (weeks).
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Observational studies reporting heart failure
Of the four studies reporting heart failure, two prospec-
tive cohort studies109 110  compared DPP-4 inhibitors ver-
sus sulfonylureas and sitagliptin versus sulfonylureas. 
One retrospective cohort study111  assessed DPP-4 
 inhibitors versus sulfonylureas and reported the find-
ings from the subgroup of DPP-4 inhibitors. Finally, 
one nested case-control study112  using claims data 
investigated use of sitagliptin versus no use in patients 
 admitted to hospital for acute coronary syndrome 
table 2 | interventions tested and event rates in randomised controlled trials
author (year)
Drug treatments used 
across groups
DPP­4 inhibitors Control Duration of 
treatment 
(weeks)type
events/analysed 
patients (no) type
events/analysed 
patients (no)
trials reporting heart failure
Arjona Ferreira (2013)a35, 36 None Sitagliptin 0/210 Glipizide 4/212 54
Arjona Ferreira (2013)b37, 38 None Sitagliptin 2/64 Glipizide 2/65 54
Bosi (2011)39 Metformin, and pioglitazone 30 mg Alogliptin 2/404 Add-on pioglitazone 15 mg 1/399 52
Ferrannini (2009)40 Metformin Vildagliptin 2/1389 Glimepiride 2/1383 52
Fonseca (2013)41 Metformin and pioglitazone Sitagliptin 0/157 Placebo 0/156 26
Garber (2007)42 Pioglitazone Vildagliptin 1/304 Placebo 1/158 24
Henry (2014)43, 44 Pioglitazone Sitagliptin 2/691 No additional drugs 0/693 54
Iwamoto (2010)45, 46 None Sitagliptin 1/290 Placebo 0/73 12
NCT00094770 (2009)47, 48, 49 Metformin Sitagliptin 2/588 Glipizide 1/584 104
NCT00103857 (2009)50, 51 Metformin Sitagliptin 1/372 No additional drugs 0/364 104
NCT00121641 (2011)52, 53 None Saxagliptin 1/306 Placebo 0/95 206
NCT00121667 (2011)54, 55 Metformin Saxagliptin 3/564 Placebo 2/179 206
NCT00286442 (2011)56, 57 Metformin Alogliptin 1/423 Placebo 0/104 26
NCT00286468 (2011)58, 59 Glyburide Alogliptin 1/401 Placebo 0/99 26
NCT00295633 (2009)60, 61, 62 TZD Saxagliptin 0/381 Placebo 1/184 76
NCT00327015 (2009)63, 64, 65 Metformin Saxagliptin 0/643 No additional drugs 2/328 24
NCT00395343 (2009)66, 67 Insulin with or without metformin Sitagliptin 0/322 Placebo 2/319 24
NCT00482729 (2009)68, 69, 70 Metformin Sitagliptin 1/625 No additional drugs 0/621 44
NCT00575588 (2010)71, 72, 73 Metformin Saxagliptin 1/428 Glipizide 1/430 104
NCT00614939 (2010)74, 75, 76 OADs and/or insulin Saxagliptin 1/85 Placebo 0/85 52
NCT00622284 (2011)77, 78 Metformin Linagliptin 3/776 Glimepiride 2/775 104
NCT00642278 (2013)79, 80 Metformin Sitagliptin 0/65 Placebo 0/65
12
Sitagliptin 0/65 Canagliflozin 1/321
NCT00707993 (2013)81, 82 None Alogliptin 1/222 Glipizide 1/219 52
NCT00757588 (2011)83, 84 Insulin with or without metformin Saxagliptin 2/304 Placebo 0/151 24
NCT00798161 (2011)85, 86 None Linagliptin 0/142 Placebo 0/72
24
Metformin Linagliptin 1/286 No additional drugs 0/291
NCT00838903 (2014)87, 88 Metformin Sitagliptin 1/302 Glimepiride 1/307
156
Sitagliptin 1/302 Placebo 0/101
NCT00856284 (2013)89, 90 Metformin Alogliptin 3/1751 Glipizide 1/878 104
NCT00954447 (2012)91 Basal insulin and/or OADs Linagliptin 3/631 Placebo 2/630 52
NCT01006603 (2013)92 None Saxagliptin 1/359 Glimepiride 3/359 52
NCT01189890 (2013)93 None Sitagliptin 0/241 Glimepiride 1/236 30
NCT01263483 (2011)94, 95 Voglibose Alogliptin 0/155 Placebo 1/75 12
NCT01289990 (2014)96 None Sitagliptin 1/223 Placebo 0/223
76
Sitagliptin 1/223 Empagliflozin 0/453
Pratley (2009)97, 98 Pioglitazone or pioglitazone, plus 
metformin or SU
Alogliptin 3/397 Placebo 0/97 26
Pratley (2014)99 None Alogliptin 0/222 Placebo 0/106
26
Metformin Alogliptin 0/220 No additional drugs 0/220
Rosenstock (2006)100 Pioglitazone Sitagliptin 0/175 Placebo 0/178 24
Rosenstock (2010)101 Pioglitazone Alogliptin 0/327 No additional drugs 0/163 26
Seino (2012)102 Metformin Alogliptin 1/188 Placebo 0/100 12
Yang (2015)103 None Anagliptin 0/68 Placebo 1/40 24
trials reporting hospital admission for heart failure
Green (2015) (TECOS)12 One or two OADs (metformin, 
pioglitazone, or SU) or insulin with or 
without metformin
Sitagliptin 228/7332 Placebo 229/7339 156*
Krum (2014) (VIVIDD)104 Standard diabetes treatment Vildagliptin 13/128 Placebo 10/124 52
Laakso (2015)105 None Linagliptin 7/113 Placebo or glimepiride 6/120 52
Scirica (2013) (SAVOR-TIMI 53)9, 106 Antihyperglycaemic drugs Saxagliptin 289/8280 Placebo 228/8212 109*
Zannad (2015) (EXAMINE)11, 107, 108 Standard of care treatment for type 2 
diabetes mellitus
Alogliptin 85/2701 Placebo 79/2679 78*
BG=biguanide; TZD=thiazolidinedione; OADs=oral antidiabetic drugs; SU=sulfonylurea.
*Median treatment time (weeks).
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(table 4  and table 5). Sample sizes ranged from 616 to 
13 185, and the mean or median length of follow-up 
ranged from one to four years. Enrolled patients had a 
mean or median age ranging from 55 to 65.8 years. 
None of the studies explicitly defined provided diag-
nostic criteria for heart failure.
Four studies used registry data, electronic health or 
medical records, or claims data for their analyses. 
Patients with type 2 diabetes were ascertained by physi-
cians in one prospective cohort study109  or by ICD-9 
Clinical Modification (CM) codes in one nested 
case-control study;112  the other two cohort studies110 111 
did not explicitly report the ascertainment of type 2 dia-
betes. None of these studies mentioned the ascertain-
ment of exposure to DPP-4 inhibitors agents and other 
confounding variables; the accuracy of ascertaining 
exposure and confounding factors was unclear. Of 
these three cohort studies, only one111  demonstrated 
that the outcome of interest was not present at start of 
study, and mentioned the method used to assess the 
outcome of interest. Of these four studies, two111 112 con-
trolled for the effect of confounding factors (web appen-
dices 4 and 5).
Effects on heart failure
All three cohort studies109-111 reported unadjusted rates 
of heart failure, involving 541 events among 16 408 
patients (raw event rate 3.3%). Because of the 
  Arjona Ferreira 2013a
  Arjona Ferreira 2013b
  Bosi 2011
  Ferrannini 2009
  Fonseca 2013
  Garber 2007
  Henry 2014
  Iwamoto 2010
  NCT00094770 2009
  NCT00103857 2009
  NCT00121641 2011
  NCT00121667 2011
  NCT00286442 2011
  NCT00286468 2011
  NCT00295633 2009
  NCT00327015 2009
  NCT00395343 2009
  NCT00482729 2009
  NCT00575588 2010
  NCT00614939 2010
  NCT00622284 2011
  NCT00642278 2013
  NCT00707993 2013
  NCT00757588 2011
  NCT00798161 2011
  NCT00838903 2014
  NCT00856284 2013
  NCT00954447 2012
  NCT01006603 2013
  NCT01189890 2013
  NCT01263483 2011
  NCT01289990 2014
  Pratley 2009
  Pratley 2014
  Rosenstock 2006
  Rosenstock 2010
  Seino 2012
  Yang 2015
Total (95% CI)
Test for heterogeneity: χ2=32.27, df=33, P=0.50, I2=0%
Test for overall eect: z=0.11, P=0.91
0.13 (0.02 to 0.96)
1.02 (0.14 to 7.38)
1.93 (0.20 to 18.58)
1.00 (0.14 to 7.08)
Not estimable
0.49 (0.03 to 9.22)
7.42 (0.46 to 118.77)
3.50 (0.03 to 464.78)
1.94 (0.20 to 18.65)
7.23 (0.14 to 364.55)
3.71 (0.04 to 372.46)
0.42 (0.05 to 3.26)
3.48 (0.03 to 478.41)
3.48 (0.03 to 475.96)
0.05 (0.00 to 3.04)
0.05 (0.00 to 0.97)
0.13 (0.01 to 2.14)
7.34 (0.15 to 370.02)
1.00 (0.06 to 16.09)
7.39 (0.15 to 372.38)
1.49 (0.26 to 8.63)
0.31 (0.00 to 82.44)
0.99 (0.06 to 15.82)
4.48 (0.24 to 85.32)
6.35 (0.12 to 324.20)
1.36 (0.08 to 22.44)
1.46 (0.18 to 11.67)
1.49 (0.26 to 8.63)
0.37 (0.05 to 2.61)
0.13 (0.00 to 6.68)
0.05 (0.00 to 3.05)
56.34 (0.60 to 5268.88)
3.49 (0.20 to 60.57)
Not estimable
Not estimable
Not estimable
4.63 (0.08 to 283.93)
0.07 (0.00 to 3.89)
0.97 (0.61 to 1.56)
5.8
5.7
4.4
5.8
-
2.6
2.9
0.9
4.4
1.5
1.1
5.3
0.9
0.9
1.3
2.6
2.9
1.5
2.9
1.5
7.3
0.7
2.9
2.6
1.4
2.8
5.2
7.3
5.8
1.5
1.3
1.1
2.7
-
-
-
1.3
1.4
100.0
0.01 0.1 1 10 100
Study
Favours DPP-4 inhibitors Favours control
Peto odds ratio
Fixed (95% CI)
Peto odds ratio
Fixed (95% CI)
Weight
(%)
0/210
2/64
2/404
2/1389
0/157
1/304
2/691
1/290
2/588
1/372
1/306
3/564
1/423
1/401
0/381
0/643
0/322
1/625
1/428
1/85
3/776
0/65
1/222
2/304
1/428
1/302
3/1751
3/631
1/359
0/241
0/155
1/223
3/397
0/442
0/175
0/327
1/188
0/68
42/15 701
DPP-4
inhibitors
4/212
2/65
1/399
2/1383
0/156
1/158
0/693
0/73
1/584
0/364
0/95
2/179
0/104
0/99
1/184
2/328
2/319
0/621
1/430
0/85
2/775
1/386
1/219
0/151
0/363
1/408
1/878
2/630
3/359
1/236
1/75
0/676
0/97
0/326
0/178
0/163
0/100
1/40
33/12 591
Control
No of events/total
Fig 2 | risk of heart failure in patients with type 2 diabetes who received DPP­4 inhibitors versus control from randomised 
controlled trials
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 heterogeneous and indirect nature of the identified 
 evidence—with substantial variations in comparisons 
and types of patients—we did not pool data across stud-
ies. The outcome information is presented in table 5.
One retrospective cohort study111  and one nested 
case-control study112  reported adjusted data. The retro-
spective cohort study, including 13 185 patients and 
with a median follow-up of four years, suggested that, 
compared with sulfonylureas, DPP-4 inhibitors was sta-
tistically associated with an increased risk of congestive 
heart failure (adjusted hazard ratio 1.10, 95% confi-
dence interval 1.04 to 1.17). The nested case-control 
study, selecting 457 heart failure cases and 4570 con-
trols, showed no statistical difference in the risk of heart 
failure between use and no use of sitagliptinin the 90 
days before acute coronary syndrome (adjusted odds 
ratio 0.75, 95% confidence interval 0.38 to 1.46, table 5). 
Using GRADE, we rated the quality of evidence in the 
identified studies as very low, owing to risk of bias, indi-
rectness, and imprecision in addition to the inherent 
risk for confounding given the observational design.
Observational studies reporting hospital admission 
for heart failure
Of the eight studies reporting hospital admission for 
heart failure, six retrospective cohort studies,13-15 113-115 
using registry data, claims data, or electronic medical 
records, assessed DPP-4 inhibitors versus active drugs 
(eg, sulfonylureas, pioglitazone), and the use of sita-
gliptin versus no use of sitagliptin. The other two 
nested case-control studies16 17  assessed use of sita-
gliptin versus no use of sitagliptin, and incretin based 
drugs (including the DPP-4 inhibitors subgroup) 
 versus other oral antidiabetic drugs (tables 4 and 5). 
The sample sizes of these eight studies ranged from 
4224 to 935 519, and the mean or median length of 
 follow-up ranged from 0.5 to 2.6 years. Enrolled 
patients had a mean age ranging from 54.6 to 67 years, 
mean baseline HbA1c level ranging from 7.5% to 8.0%, 
and a mean duration of diabetes ranging from 2.3 to 
8.6 years.
The eight studies used registry data, claims data, or 
electronic medical records for analyses. Only two stud-
ies15 113  explicitly reported use of ICD codes to ascertain 
patients with diabetes; one study13  ascertained expo-
sure to DPP-4 inhibitors by using anatomical therapeu-
tic chemical classes; three studies13 15 113  explicitly stated 
use of ICD codes to ascertain other confounding vari-
ables. Four studies13 15 113 114  used ICD-9 or ICD-10 codes 
to assess outcomes. Three cohort studies13 113 114 clarified 
that the outcome of interest was not present at enrol-
ment. All eight studies controlled for potential con-
founding factors, but failed to specify the extent to 
which the data were complete in the database (web 
appendices 4 and 5).
Effects on hospital admission for heart failure
All but one retrospective cohort study115  reported 
unadjusted rates of hospital admission for heart fail-
ure. The five cohort studies13-15 113 114 included 3500 
events among 1 630 884 patients (raw event rate 0.2%; t
ab
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1466 events (0.2%) in 912 309 patients from the DPP-4 
inhibitors group, and 2034 events (0.3%) in 718 575 
patients from the control group). The two nested 
case-control studies16 17 involved 1942 cases among 
27 806 patients. Because of the variety of confounding 
factors investigated in the studies, we did not pool the 
unadjusted data.
All eight studies reported adjusted estimates of hos-
pital admission for heart failure. Of these, six studies—
five cohort studies and one nested case-control 
study—compared DPP-4 inhibitors with active drugs 
(sulfonylureas, pioglitazone, other oral antidiabetic 
drugs). Pooling of adjusted estimates from these six 
studies showed that DPP-4 inhibitors were associated 
with reduced risk of hospital admission for heart failure 
(adjusted odds ratio 0.85, 95% confidence interval 0.74 
to 0.97; I2=31%). However, pooling of the cohort study15 
(16 576 patients and 614 events), and the nested 
case-control study16 (824 cases and 8238 controls) sug-
gested a non-significant trend for increased risk of 
admission for heart failure compared with no use of 
sitagliptin (adjusted odds ratio 1.41, 0.95 to 2.09; 
I2=65%). There was significant subgroup effect by type 
of control (interaction P=0.02, fig 4). Using GRADE, we 
rated the quality of evidence as very low, due to risk of 
bias, heterogeneity, and imprecision in addition to the 
inherent risk for confounding given the observational 
design.
Table 6 summarises the evidence regarding the 
effects of DPP-4 inhibitors on heart failure or hospital 
admission for heart failure.
discussion
Main findings
The only evidence of moderate quality from our results 
is from randomised controlled trials that examined the 
effect of DPP-4 inhibitors on hospital admission for 
heart failure. These studies suggested a small increase, 
in both relative and absolute terms, in heart failure 
admissions in patients using DPP-4 inhibitors than 
those not. The results, however, are of borderline signif-
icance. Evidence from observational studies is of very 
low quality, and thus has little bearing on any infer-
ences about DPP-4 inhibitor effects on heart failure 
admission.
With respect to the incidence of heart failure, trial 
evidence leaves uncertainty regarding the relative effect 
of DPP-4 inhibitors. Because the follow-up was rela-
tively short and the baseline risk of patients was very 
low in those trials, the incidence of heart failure was 
very low (well under 1% per year), and with the small 
number of events, the confidence intervals around rela-
tive effects are wide. In addition, heart failure was 
unspecified in all but one of the phase III trials. Many 
(87%) reported heart failure as serious adverse events, 
in which admission for heart failure might have been 
included according to the definition of serious adverse 
events. The pooled estimate could thus represent a 
composite of heart failure with or without admission for 
heart failure. The observational studies again provide 
very low quality evidence and have little effect on infer-
ences, although results are consistent. Overall, the cur-
rent evidence provides no support for the hypothesis 
that DPP-4 inhibitors increase the incidence of heart 
failure.
strengths and limitations
Our study has several strengths. Firstly, we used rigor-
ous methods to systematically identify and include data 
from both randomised and non-randomised studies to 
examine the effect of DPP-4 inhibitors on risk of heart 
failure and hospital admission for heart failure. Sec-
ondly, in addition to published reports, we have identi-
fied additional data from ClinicalTrials.gov. Our study 
included four randomised controlled trials and three 
observational studies that were not published in jour-
nals. Thirdly, we instituted a rigorous approach to 
ensure the data were accurate. In particular, we care-
fully checked the data reported in ClinicalTrials.gov 
and journal publications for consistency. Fourthly, we 
addressed several prespecified subgroup analyses to 
explore sources of heterogeneity. Finally, we used 
GRADE to assess the quality of the body of evidence.
Our study also had some limitations. Firstly, for var-
ious reasons, some trials are likely not to report out-
come data in their full publications. However, we have 
obtained additional data through the search of the 
ClinicalTrials.gov and conference abstracts, which 
minimised the risk of outcome reporting bias. Sec-
ondly, given the limitations of reported data, we were 
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unable to confirm whether the increased risk of hospi-
tal admission for heart failure was a class effect or a 
specific effect of saxagliptin. Other limitations 
included those of the primary studies, such as the risk 
of bias of observational studies, the potentially vari-
able specification of outcomes (heart failure and hos-
pital admission for heart failure), and the likelihood of 
variable and incomplete ascertainment of heart failure 
in the clinical trials.
Comparison with other studies
Four previous meta-analyses7 117 118 119  have explored the 
effect of DPP-4 inhibitors on the risk of heart failure. Of 
those studies, one7  found that treatment with DPP-4 
inhibitors for 29 weeks or longer was associated with an 
increased risk of new onset of heart failure (risk ratio 
1.16, 95% confidence interval 1.01 to 1.33), but not with 
treatment for less than 29 weeks (0.67, 0.32 to 1.40). The 
second117  included 24 randomised controlled trials that 
DPP-4 inhibitors v active drugs
  Fadini 2015
  Fu 2015
  Seong 2015
  Suh 2015
  Velez 2015
  Yu 2015
Subtotal (95% CI)
Test for heterogeneity: τ2=0.01, χ2=7.24, df=5, P=0.20, I2=31%
Test for overall e ect: z=2.45, P=0.01
Sitagliptin use v no use
  Wang 2014
  Weir 2014
Subtotal (95% CI)
Test for heterogeneity: τ2=0.06, χ2=2.85, df=1, P=0.09, I2=65%
Test for overall e ect: z=1.70, P=0.09
Test for subgroup di erences:  χ2=5.71, df=1, P=0.02, I2=83%
0.78 (0.62 to 0.98)
0.87 (0.73 to 1.04)
0.44 (0.10 to 1.91)
0.99 (0.83 to 1.19)
0.58 (0.38 to 0.88)
0.88 (0.63 to 1.22)
0.85 (0.74 to 0.97)
1.21 (1.04 to 1.41)
1.84 (1.16 to 2.92)
1.41 (0.95 to 2.09)
21.9
28.5
0.8
27.7
8.6
12.6
100.0
64.0
36.0
100.0
0.2 0.5 1 2 5
Study or subgroup
Favours DPP-4 inhibitors Favours control
Odds ratio, IV
Random (95% CI)
Odds ratio, IV
Random (95% CI)
Weight
(%)
-0.249
-0.139
-0.821
-0.010
-0.545
-0.128
0.191
0.610
Log (odds ratio)
0.114
0.090
0.750
0.093
0.214
0.169
0.080
0.236
SE
Fig 4 | risk of hospital admission for heart failure in patients with type 2 diabetes who received DPP­4 inhibitors versus 
control based on adjusted data from observational studies. se=standard error; iv=inverse variance
table 6 | risk of heart failure or hospital admission for heart failure among patients with type 2 diabetes receiving DPP­4 inhibitor treatment
Comparison
no of studies (events 
or cases, patients)
DPP­4 inhibitors 
(events/patients)
Control (events/
patients) effect estimate (95%Ci)
Cardiovascular 
morbidities at baseline
Heart failure
Randomised controlled trials
 DPP-4 inhibitors v control 38 (75, 28 292) 42/15 701 33/12 591 Pooled OR 0.97 (0.61 to 1.56) Typically without CVD
Observational studies
 DPP-4 inhibitors v SU 1 (11, 616) 8/436 3/153 Unadjusted OR 0.88 (0.22 to 3.48) With or without CVD
 DPP-4 inhibitors v SU 1 (528, 13 185) NR NR Adjusted HR 1.10 (1.04 to 1.17) No history of CVD or 
congestive heart failure
 Sitagliptin v SU 1 (2, 2607) 1/1874 1/733 Unadjusted OR 0.39 (0.02 to 6.26) NR
 Sitagliptin use v no use 1 (457, 5027) — — Adjusted OR 0.75 (0.38 to 1.46) Admission to hospital for 
an acute coronary 
syndrome event
Hospital admission for heart failure
Randomised controlled trials
 DPP-4 inhibitors v control 5 (1174, 37 028) 622/18 554 522/18 474 Pooled OR 1.13 (1.00 to 1.26) CVD or multiple risk 
factors for vascular 
disease
Observational studies
  DPP-4 inhibitors v active control 
(pooled estimates)
6 (4341, 1 618 295) — — Pooled adjusted OR 0.85 (0.74 to 0.97) With or without CVD
 DPP-4 inhibitors v SU 3 (1875, 657 596) 380/202 292 1495/455 304 Adjusted HR 0.84 (0.74 to 0.96) With or without CVD
 DPP-4 inhibitors v pioglitazone 2 (1060, 1 031 432) 796/776 449 264/254 983 Adjusted HR 0.67 (0.57 to 0.78) With or without CVD
 DPP-4 inhibitors v other OADs 1 (1118, 18 744)* Adjusted OR 0.88 (0.63 to 1.22) With or without CVD
 DPP-4 inhibitors v control 1 (127, 3987) NR NR Adjusted HR 0.58 (0.38, 0.88) With or without CVD
  Sitagliptin use v no use (pooled 
estimates)
2 (1438, 25 638) — — Pooled adjusted OR 1.41 (0.95 to 2.09) —
 Sitagliptin use v no use 1 (614, 16 576) 339/8288 275/8288 Adjusted HR 1.21 (1.04 to 1.42) With or without CVD
 Sitagliptin use v no use 1 (824, 9062)* Adjusted OR 1.84 (1.16 to 2.92) Heart failure at baseline
CVD=cardiovascular disease; SU=sulfonylurea; OR=odds ratio; HR=hazard ratio; NR=not reported; OADs=oral antidiabetic drugs.
*Nested case-control study.
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enrolled no less than 100 patients and followed up 
patients for 24 weeks; the third118  exclusively included 
37 trials for analysis; the fourth119 included trials and 
observational studies. All the last three studies found 
that DPP-4 inhibitors were statistically associated with 
an increased risk of heart failure (risk ratio 1.16 (1.01 to 
1.33), odds ratio 1.19 (1.03 to 1.37), odds ratio 1.15 (1.02 to 
1.29), respectively).
Compared with these studies, our review has added 
substantial information. Firstly, we separately 
addressed heart failure and hospital admission as a 
result of heart failure. Secondly, we included both 
observational studies and randomised controlled trials. 
With respect to the trials, two important large trials11 12 
were published subsequent to the previous reviews and 
allowed us to analyse the effect of DPP-4 inhibitors on 
hospital admission for heart failure. We also included 
additional large observational studies that carry 
important information regarding the risk of heart fail-
ure or admission for heart failure.
Our findings regarding the effect of DPP-4 inhibitors 
on heart failure were not consistent with previous 
meta-analyses. This difference is probably due to the 
fact that the previous studies were dominated by large 
trials reporting positive association with hospital 
admission for heart failure (eg, SAVOR TIMI-53), and 
more recent trials that have failed to find an effect were 
not considered.
We also found all four meta-analyses in our study7 117-119 
to have several methodological issues. Firstly, these 
reviews have pooled data for heart failure and hospital 
admissions for heart failure. We believe that a more 
appropriate analysis should consider the two outcomes 
separately. We identified varying results when analys-
ing the two outcomes separately. More importantly, the 
pooling of the two outcomes together would probably 
result in misleading effect estimates, when the authors 
aimed to assess the effect of DPP-4 inhibitors on the risk 
of heart failure. Another meta-analysis7  investigated 
DPP-4 inhibitors on the risk of new onset of heart fail-
ure, but this study included trials, such as SAVOR TIMI-
53 and EXAMINE that already included patients with 
heart failure at baseline. The third meta-analysis117 
failed to include outcome data published in ClinicalTri-
als.gov. The final meta-analysis119 combined ran-
domised controlled trials and observational studies to 
generate grand effect estimates. Because of the sub-
stantial differences in the design and analysis of the 
type of studies, and the considerable variation in obser-
vational studies, the grand pooling will introduce mis-
leading findings.
implications for practice
The current evidence suggests a possible increased 
risk of hospital admission for heart failure in those 
patients with type 2 diabetes treated with DPP-4 
inhibitors and with cardiovascular diseases or multi-
ple risk factors for vascular diseases at baseline. 
Although the effect is small if it exists, and the associ-
ated confidence interval includes no effect, our results 
suggest the advisability of caution in the use of DPP-4 
inhibitors for patients with type 2 diabetes who are at 
high risk for heart failure.
Conclusions
The relative effect of DPP-4 inhibitors on heart failure 
remains uncertain in patients with type 2 diabetes, 
given the relatively short follow-up and low quality of 
evidence. The current evidence suggests a small 
increase in the risk of hospital admission for heart fail-
ure in patients with existing cardiovascular diseases 
or multiple risk factors for vascular diseases. Addi-
tional randomised controlled trials enrolling patients 
with existing cardiovascular diseases or multiple risk 
factors for vascular diseases will be required to defini-
tively assess the effect of DPP-4 inhibitors on such 
patients. Such trials, if enrolling patients at high risk 
of exacerbation and admission, may be feasible. In the 
meantime, the possible increase in hospital admission 
for heart failure could be one issue that patients and 
clinicians consider in choosing antidiabetic drug 
treatment for patients with existing cardiovascular 
diseases.
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